Petrelintide Induces 10% Weight Loss, High Tolerability

Why It Matters

If confirmed in later phases, petrelintide could expand the obesity‑treatment arsenal with a modest‑weight‑loss, low‑side‑effect option, appealing to primary‑care clinicians and patients hesitant about GLP‑1 side effects.

Key Takeaways

• Weekly petrelintide achieved up to 10.7% weight loss
• Adverse events similar to placebo; serious events <4%
• Improved waist circumference, triglycerides, and hs‑CRP
• Amylin‑based option may be better tolerated than GLP‑1

Pulse Analysis

Obesity management has been dominated by GLP‑1 agonists, which deliver strong weight loss but often trigger gastrointestinal discomfort and elevated pulse rates. Clinicians and patients alike have been seeking alternatives that maintain efficacy while reducing side effects. Amylin‑based therapies, such as petrelintide, target a different hormonal pathway, offering a complementary mechanism that could broaden therapeutic choices for the roughly 100 million American adults living with obesity.

The phase 2 ZUPREME‑1 study enrolled 493 participants across the United States, Poland, and Romania, randomizing them to five escalating doses of weekly petrelintide or placebo. At 42 weeks, the highest dose produced a mean 10.7% reduction in body weight versus 1.7% for placebo, meeting the primary endpoint with statistical significance (P < .001). Safety data were encouraging: overall adverse events occurred in 70.8% of the petrelintide group versus 69.1% for placebo, and serious events were under 4% in both arms. Notably, gastrointestinal issues were mild, and pulse rates declined—a contrast to the tachycardia sometimes observed with GLP‑1 agents.

Should phase 3 trials replicate these findings, petrelintide could reshape the obesity‑drug market by positioning amylin analogs as first‑line, primary‑care‑friendly options. Its modest yet clinically meaningful weight loss, coupled with a tolerability profile resembling placebo, may attract patients reluctant to start GLP‑1 therapy. Pharmaceutical investors will likely monitor upcoming data closely, as Roche and Zealand Pharma could leverage this platform to diversify their metabolic pipelines and capture a share of the multi‑billion‑dollar weight‑management market.